* Shares in Glenmark Pharmaceuticals gain 2.5 percent
after U.S. health regulators approved Salix Pharmaceuticals
Ltd's drug to treat diarrhoea in HIV/AIDS patients on
qantiretroviral therapy, a combination of medicines used to
treat HIV infection.
* Glenmark will be the active pharmaceutical ingredients
supplier for the drug to Salix in regulated markets.
* An international arbitrator ruled in August 2012 that Glenmark
Pharmaceuticals has the right to sell its HIV-associated
diarrhoea drug Crofelemer in 140 countries.
* Edelweiss in a report says, "The overall potential market for
Crofelemer is anticipated at $300 million-$500 million and peak
potential revenue for Glenmark, from API supply, could be $15
million-$20 million per annum."